title: Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans.
abstract: Chemotherapeutic agents are used in the treatment of many cancers, yet variable resistance and toxicities among individuals limit successful outcomes. Several studies have indicated outcome differences associated with ancestry among patients with various cancer types. Using both traditional SNP-based and newly developed gene-based genome-wide approaches, we investigated the genetics of chemotherapeutic susceptibility in lymphoblastoid cell lines derived from 83 African Americans, a population for which there is a disparity in the number of genome-wide studies performed. To account for population structure in this admixed population, we incorporated local ancestry information into our association model. We tested over 2 million SNPs and identified 325, 176, 240, and 190 SNPs that were suggestively associated with cytarabine-, 5'-deoxyfluorouridine (5'-DFUR)-, carboplatin-, and cisplatin-induced cytotoxicity, respectively (p≤10(-4)). Importantly, some of these variants are found only in populations of African descent. We also show that cisplatin-susceptibility SNPs are enriched for carboplatin-susceptibility SNPs. Using a gene-based genome-wide association approach, we identified 26, 11, 20, and 41 suggestive candidate genes for association with cytarabine-, 5'-DFUR-, carboplatin-, and cisplatin-induced cytotoxicity, respectively (p≤10(-3)). Fourteen of these genes showed evidence of association with their respective chemotherapeutic phenotypes in the Yoruba from Ibadan, Nigeria (p<0.05), including TP53I11, COPS5 and GAS8, which are known to be involved in tumorigenesis. Although our results require further study, we have identified variants and genes associated with chemotherapeutic susceptibility in African Americans by using an approach that incorporates local ancestry information.
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, United States of America.
authors.forename: Heather E
authors.initials: HE
authors.lastname: Wheeler
authors.forename: Lidija K
authors.initials: LK
authors.lastname: Gorsic
authors.forename: Marleen
authors.initials: M
authors.lastname: Welsh
authors.forename: Amy L
authors.initials: AL
authors.lastname: Stark
authors.forename: Eric R
authors.initials: ER
authors.lastname: Gamazon
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Cox
authors.forename: M Eileen
authors.initials: ME
authors.lastname: Dolan
mesh_terms: D001741:Black or African American / Q000235:genetics*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016190:Carboplatin / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D002648:Child; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics*; D005260:Female; D005789:Genealogy and Heraldry; D005796:Genes; D015894:Genome, Human / Q000235:genetics; D055106:Genome-Wide Association Study; D006801:Humans; D008297:Male; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D015206:Southwestern United States
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin